Preoperative CTLA-4 blockade: Tolerability and immune monitoring in the setting of a presurgical clinical trial Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antigens, CD
  • Carcinoma, Transitional Cell
  • Neoadjuvant Therapy
  • Urinary Bladder Neoplasms

abstract

  • Our trial shows that anti-CTLA-4 therapy has a tolerable safety profile in the presurgical setting and that a preoperative model can be used to obtain biological data on human immune responses, which can efficiently guide the monitoring of patients treated in the metastatic disease setting.

publication date

  • May 15, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2919850

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-10-0569

PubMed ID

  • 20460488

Additional Document Info

start page

  • 2861

end page

  • 71

volume

  • 16

number

  • 10